International Variation in Female Breast XXXX Incidence and Mortality Rates.

@entity5 @entity1 @entity204 @entity0
BACKGROUND: @entity0 is the most frequently diagnosed @entity5 and the leading cause of @entity5 -related @entity204 among @entity1 worldwide. Herein, we examine global trends in female @entity0 rates using the most up-to-date data available. METHODS: @entity0 incidence and mortality estimates were obtained from GLOBOCAN 2012 (globocan.iarc.fr). We analyzed trends from 1993 onward using incidence data from 39 countries from the International Agency for Research on @entity5 and mortality data from 57 countries from the World Health Organization. RESULTS: Of 32 countries with incidence and mortality data, rates in the recent period diverged-with incidence increasing and mortality decreasing-in nine countries mainly in Northern/Western Europe. Both incidence and mortality decreased in France, Israel, Italy, Norway, and Spain. In contrast, incidence and @entity204 rates both increased in Colombia, Ecuador, and Japan. @entity204 rates also increased in Brazil, Egypt, Guatemala, Kuwait, Mauritius, Mexico, and Moldova. CONCLUSIONS: @entity0 mortality rates are decreasing in most high-income countries, despite increasing or stable incidence rates. In contrast and of concern are the increasing incidence and mortality rates in a number of countries, particularly those undergoing rapid changes in @entity1 development. Wide variations in @entity0 rates and trends reflect differences in patterns of risk factors and access to and availability of early detection and timely treatment. IMPACT: Increased awareness about @entity0 and the benefits of early detection and improved access to treatment must be prioritized to successfully implement @entity0 control programs, particularly in transitioning countries. @entity5 Epidemiol Biomarkers Prev; 24(10); 1-12.   2015 AACR.
